- Home
- TNGX
as 05-30-2025 4:00pm EST
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 248.2M | IPO Year: | N/A |
| Target Price: | $12.20 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $12.02 | Next Earning Date: | 05-12-2025 |
| Revenue: | $40,990,000 | Revenue Growth: | 10.09% |
| Revenue Growth (this year): | -31.06% | Revenue Growth (next year): | -13.01% |
Latest Tango Therapeutics Inc. News
TNGX Breaking Stock News: Dive into TNGX Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
GlobeNewswire
11 days ago
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
Simply Wall St.
17 days ago
Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price
Simply Wall St.
18 days ago
Tango Therapeutics First Quarter 2025 Earnings: Misses Expectations
GlobeNewswire
20 days ago
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
GuruFocus.com
23 days ago
Tango Therapeutics Inc (TNGX) Q1 2025 Earnings Report Preview: What To Look For
GlobeNewswire
a month ago
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
GlobeNewswire
2 months ago
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
Compare TNGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNGX Tango Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.